PharmTech Drug Digest 11.20
News|Articles|March 2, 2016

TxCell Launches Industrialization Laboratories and Technology Transfer Academy

TxCell’s new facilities are based in Sophia Antipolis, France, on the premises of GenBiotech.

TxCell, a biotechnology company developing personalized cellular immunotherapies using regulatory T-cells to treat chronic inflammatory and autoimmune diseases, announced the launch of its new process industrialization laboratories and technology transfer academy facilities in Sophia Antipolis, France, according to a Feb. 29, 2016 press announcement. The new facilities will be based in Sophia Antipolis, on the premises of GenBiotech, an affiliate company of the Genevrier Laboratories. 

According to the company, the facilities will be used to improve the existing TxCell manufacturing process for its ASTrIA platform, as well as development and manufacturing of its ENTrIA platform. The facilities will also host the TxCell Academy for Technology Transfer. The academy will be responsible for educating and training all contract manufacturing partners. It will also train future strategic partners on the manufacturing processes of TxCell’s personalized cellular therapies.

Source: TxCell 


Related to this article

white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Green Chemistry Supply and Demand in Sustainable Pharma
Celtic Renewables won the CPHI Award for Sustainable Pharma Excellence for its green chemicals used in pharmaceutical manufacturing. Bettina Brierley, chief commercial officer, talks about the adoption, capacity, and pricing of biosolvents.